Home

Classified by application

All Products

Signaling Pathways

Research Areas

Nature products

Antibodies

Peptides

Catalysts

Impurities

Intermediate

Raw Materials

Antibodies

Chemical Structure Cat. No. Product Name CAS No.
Ramucirumab Chemical Structure
BCP26258 Ramucirumab 947687-13-0
Ramucirumab is a human VEGFR-2 antagonist for the treatment of solid tumors. Ramucirumab is a recombinant human immunoglobulin G1 monoclonal antibody that binds to the extracellular binding domain of VEGFR-2 and prevents the binding of VEGFR ligands: VEGF-A, VEGF-C, and VEGF-D.
Vedolizumab Chemical Structure
BCP26256 Vedolizumab 943609-66-3
Vedolizumab is a humanized monoclonal antibody that targets the α4β7 integrin for the treatment of ulcerative colitis and Crohn's disease.
Ozanezumab Chemical Structure
BCP23507 Ozanezumab 1310680-64-8
Ozanezumab is a monoclonal antibody.
Sacituzumab govitecan Chemical Structure
BCP28938 Sacituzumab govitecan 1491917-83-9
Sacituzumab Govitecan is an antibody drug conjugate containing the humanized monoclonal antibody, hRS7, against tumor-associated calcium signal transducer 2 (TACSTD2 or TROP2) and linked to the active metabolite of irinotecan, 7-ethyl-10-hydroxycamptothecin (SN-38), with potential antineoplastic activity.
Sarilumab Chemical Structure
BCP31891 Sarilumab 1189541-98-7
Sarilumab is a human monoclonal antibody against the interleukin-6 receptor.
Evolocumab Chemical Structure
BCP25203 Evolocumab 1256937-27-5
Evolocumab is a monoclonal antibody designed to bind to PCSK9 and inhibit PCSK9 from binding to LDL receptors on the liver surface. In the absence of PCSK9, there are more LDL receptors on the surface of liver cells to remove LDL-C from the blood.
Ixekizumab Chemical Structure
BCP29780 Ixekizumab 1143503-69-8
Ixekizumab is a humanized immunoglobulin G subclass 4 (IgG4) monoclonal antibody (mAb) against interleukin-17A (IL-17A) and prevents it from interacting with the IL-17A receptor.
Gemtuzumab Chemical Structure
BCP30538 Gemtuzumab 220578-59-6
Gemtuzumab is a monoclonal antibody to CD33 linked to a cytotoxic agent from the class of calicheamicins.
Canakinumab Chemical Structure
BCP30537 Canakinumab 914613-48-2
Canakinumab is a human monoclonal antibody targeted at interleukin-1 beta.
Brentuximab Vedotin Chemical Structure
BCP30536 Brentuximab Vedotin 914088-09-8
Brentuximab vedotin is an antibody-drug conjugate medication used to treat relapsed or refractory Hodgkin lymphoma (HL) and systemic anaplastic large cell lymphoma (ALCL). It selectively targets tumor cells expressing the CD30 antigen, a defining marker of Hodgkin lymphoma and ALCL (a type of T cell non-Hodgkin lymphoma).
123下一页末页共 61 条记录 1 / 7 页 
0086-13720134139